A combined CoMFA and CoMSIA 3D-QSAR study of benzamide type antibacterial inhibitors of the FtsZ protein in drug-resistant Staphylococcus aureus

References

• Infectious Diseases Society of America, Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates—A Public Health Crisis Brews, Infectious Diseases Society of America, Arlington, VA, 2004.
   Google Scholar
• M.A. Fischbach and C.T. Walsh, Antibiotics for emerging pathogens, Science 325 (2009), pp. 1089–1093.
   PubMed Web of Science ®Google Scholar
• E.W. Koneman and S. Allen, Diagnostico Microbiologico/Microbiological diagnosis: Texto Y Atlas En Color/Text and Color Atlas, Ed. Médica Panamericana, Madrid, 2008.
   Google Scholar
• T. Frieden, Antibiotic Resistance Threats in the United States, 2013, Tech. Rep. Centers for Disease Control and Prevention, Atlanta, GA, 2013.
   Google Scholar
• World Health Organization, Antimicrobial Resistance: Global Report on Surveillance, Geneva, 2014.
   Google Scholar
• H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett, Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America, Clin. Infect. Dis. 48 (2009), pp. 1–12.
   PubMed Web of Science ®Google Scholar
• P. de Boer, R. Crossley, and L. Rothfield, The essential bacterial cell-division protein FtsZ is a GTPase, Nature 359 (1992), pp. 254–256.
   PubMed Web of Science ®Google Scholar
• D.J. Haydon, J.M. Bennett, D. Brown, I. Collins, G. Galbraith, P. Lancett, R. Macdonald, N.R. Stokes, P.K. Chauhan, J.K. Sutariya, N. Nayal, A. Srivastava, J. Beanland, R. Hall, V. Henstock, C. Noula, C. Rockley, and L. Czaplewski, Creating an antibacterial with in vivo efficacy: Synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties, J. Med. Chem. 53 (2010), pp. 3927–3936.
   PubMed Web of Science ®Google Scholar
• S. Ma, C. Cong, X. Meng, S. Cao, H. Yang, Y. Guo, X. Lu, and S. Ma, Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ, Bioorg. Med. Chem. Lett. 23 (2013), pp. 4076–4079.
   PubMed Web of Science ®Google Scholar
• N.R. Stokes, N. Baker, J.M. Bennett, J. Berry, I. Collins, L.G. Czaplewski, A. Logan, R. Macdonald, L. Macleod, H. Peasley, J.P. Mitchell, N. Nayal, A. Yadav, A. Srivastava, and D.J. Haydon, An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy, Antimicrob. Agents Chemother. 57 (2013), pp. 317–325.
   PubMed Web of Science ®Google Scholar
• N.R. Stokes, N. Baker, J.M. Bennett, P.K. Chauhan, I. Collins, D.T. Davies, M. Gavade, D. Kumar, P. Lancett, R. Macdonald, L. MacLeod, A. Mahajan, J.P. Mitchell, N. Nayal, Y.N. Nayal, G.R.W. Pitt, M. Singh, A. Yadav, A. Srivastava, L.G. Czaplewski, and D.J. Haydon, Design, synthesis and structure–activity relationships of substituted oxazole–benzamide antibacterial inhibitors of FtsZ, Bioorg. Med. Chem. Lett. 24 (2014), pp. 353–359.
   PubMed Web of Science ®Google Scholar
• D.J. Haydon, N.R. Stokes, R. Ure, G. Galbraith, J.M. Bennett, D.R. Brown, P.J. Baker, V.V. Barynin, D.W. Rice, and S.E. Sedelnikova, An inhibitor of FtsZ with potent and selective anti-staphylococcal activity, Science 321 (2008), pp. 1673–1675.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967.
   PubMed Web of Science ®Google Scholar
• G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130–4146.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard, 7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, 2006.
   Google Scholar
• T.I. Oprea, C.L. Waller, and G.R. Marshall, Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes, J. Med. Chem. 37 (1994), pp. 2206–2215.
   PubMed Web of Science ®Google Scholar
• SYBYL-X 1.2, Tripos International, St. Louis, MS.
   Google Scholar
• J.G. Vinter, A. Davis, and M.R. Saunders, Strategic approaches to drug design. I. An integrated software framework for molecular modelling, J Comput Aided Mol Des 1 (1987), pp. 31–51.
   PubMedGoogle Scholar
• J. Gasteiger and M. Marsili, Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges, Tetrahedron 36 (1980), pp. 3219–3228.
   Web of Science ®Google Scholar
• M. Clark, R.D. Cramer, and N. Van Opdenbosch, Validation of the general purpose Tripos 5.2 force field, J. Comput. Chem. 10 (1989), pp. 982–1012.
   Web of Science ®Google Scholar
• B.L. Bush and R.B. Nachbar, Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA, J. Comput.-Aided Mol. Design 7 (1993), pp. 587–619
   Google Scholar
• C.L. Waller, T.I. Oprea, A. Giolitti, and G.R. Marshall, Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules, J. Med. Chem. 36 (1993), pp. 4152–4160.
   PubMed Web of Science ®Google Scholar
• L.G. Czaplewski, I. Collins, E.A. Boyd, D. Brown, S.P. East, M. Gardiner, R. Fletcher, D.J. Haydon, V. Henstock, P. Ingram, C. Jones, C. Noula, L. Kennison, C. Rockley, V. Rose, H.B. Thomaides-Brears, R. Ure, M. Whittaker, and N.R. Stokes, Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ, Bioorg. Med. Chem. Lett. 19 (2009), pp. 524–527.
   PubMed Web of Science ®Google Scholar